Literature DB >> 8443140

Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia.

W H Sheu1, S M Shieh, M M Fuh, D D Shen, C Y Jeng, Y D Chen, G M Reaven.   

Abstract

Plasma glucose and insulin responses to oral glucose and mixed meals and the ability of insulin to stimulate glucose disposal were quantified in normal volunteer subjects and patients with types IIA, IIB, and IV hyperlipoproteinemia (HLP). The results indicated that patients with either type IIB or IV HLP had higher plasma glucose (p < 0.05-< 0.001) and insulin (p < 0.001) responses to both oral glucose and mixed meals compared with the normal subjects and patients with type IIA HLP. Steady-state plasma glucose concentrations (mmol/L) were also higher (p < 0.001) in patients with types IIB (13.3 +/- 0.6) and IV (12.8 +/- 1.2) HLP during a continuous infusion of somatostatin, glucose, and insulin than either the control group (volunteer subjects) (6.2 +/- 0.9) or patients with type IIA HLP (5.6 +/- 1.0). Because the steady-state plasma insulin concentrations were similar in all four groups, patients with either type IIB or IV HLP were resistant to insulin-mediated glucose uptake. These data indicate that patients with hypertriglyceridemia are insulin resistant, glucose intolerant, and hyperinsulinemic, irrespective of the plasma cholesterol concentration. The results further demonstrate that hypercholesterolemic patients with normal triglyceride concentrations do not have any abnormalities of glucose and insulin metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443140     DOI: 10.1161/01.atv.13.3.367

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  10 in total

Review 1.  Diet and Syndrome X.

Authors:  G M Reaven
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

2.  Statin-induced diabetes: how important is insulin resistance?

Authors:  F Abbasi; G M Reaven
Journal:  J Intern Med       Date:  2014-09-25       Impact factor: 8.989

Review 3.  Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment.

Authors:  A N Nafziger
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 4.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

Authors:  Surapon Tangvarasittichai
Journal:  World J Diabetes       Date:  2015-04-15

5.  Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects--evidence against a modulating role for insulin.

Authors:  V Mohamed-Ali; M M Gould; S Gillies; S Goubet; J S Yudkin; A P Haines
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

6.  Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia.

Authors:  A Curtin; P Deegan; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Acta Diabetol       Date:  1995-12       Impact factor: 4.280

7.  Statins Are Associated With Increased Insulin Resistance and Secretion.

Authors:  Fahim Abbasi; Cindy Lamendola; Chelsea S Harris; Vander Harris; Ming-Shian Tsai; Pragya Tripathi; Fakhar Abbas; Gerald M Reaven; Peter D Reaven; Michael P Snyder; Sun H Kim; Joshua W Knowles
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-26       Impact factor: 8.311

Review 8.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

9.  Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment.

Authors:  K Malminiemi
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

10.  Relationship between simple markers of insulin resistance and coronary artery calcification.

Authors:  Gerald M Reaven; Joshua W Knowles; David Leonard; Carolyn E Barlow; Benjamin L Willis; William L Haskell; David J Maron
Journal:  J Clin Lipidol       Date:  2017-06-06       Impact factor: 4.766

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.